艾司奥美拉唑镁肠溶胶囊联合康复新液治疗胃食管反流病患者的临床疗效研究

Clinical Effect of Esomeprazole Magnesium Enteric-coated Capsule Combined with Kangfuxin Liquid in the Treatment of Patients with Gastroesophageal Reflux Patients

目的 探讨艾司奥美拉唑镁肠溶胶囊联合康复新液治疗胃食管反流病患者的临床疗效。方法 选择我院2021年1月至2022年12月收治的150例胃食管反流病患者,根据不同治疗方案将其分为75例观察组和75例对照组,对照组患者应用艾司奥美拉唑镁肠溶胶囊进行治疗,观察组患者联合艾司奥美拉唑镁肠溶胶囊与康复新液进行治疗,比较两组患者的临床治疗效果,治疗前后ProGRP血清胃泌素释放肽前体、PGI胃蛋白酶原Ⅰ、PGⅡ胃蛋白酶原Ⅱ水平的改善情况,患者胃灼热、反流和胸骨后疼痛症状的GerdQ积分改善效果、内镜检查改善情况以及发生头痛、恶心呕吐、腹胀的不良反应。结果 治疗后观察组总有效率达到90.7%,高于对照组的76%(P <0.05)。治疗后两组患者内镜检查结果均得到改善,其中观察组患者0级患者比例明显增多,其改善情况优于对照组(P <0.05)。两组患者经过治疗后胃灼热、反流和胸骨后疼痛症状积分均降低,且观察组患者低于对照组(P <0.05)。两组患者经治疗后ProGRP指标升高,PGⅠ、PGⅡ指标降低,但治疗后的各项指标相比差异无显著性(P <0.05)。观察组患者不良反应发生率为4%,低于对照组的13.3%(P <0.05)。结论 艾司奥美拉唑镁肠溶胶囊是临床治疗胃食管反流病患者的常用且有效药物,但单一用药效果有限,患者易出现腹胀等不良反应,因此建议联合其他药物如康复新液进行治疗,可提高疗效,改善症状和相关指标,减少不良反应的发生。

Objective To investigate the clinical effect of Esomeprazole magnesium enteric-coated capsules combined with kangfuxin liquid in the treatment of patients with gastroesophageal reflux.Methods A total of 150 patients with gastroesophageal reflux disease admitted to our hospital from January 2021 to December 2022 were selected and divided into 75 observation group and 75 control group combined with different treatment regiments.Patients in the control group were treated with Esomeprazole magnesium enteric-coated capsules.Patients in the observation group were treated with esomeprazole magnesium enteric-coated capsule and kangfuxin liquid.The clinical therapeutic effect of the two groups was compared,and the improvement of serum gastrin-releasing peptide precursor,PGI pepsinogenⅠ,PPⅡpepsinogenⅡlevels before and after treatment.Improvement of GerdQ scores,improvement of endoscopy,headache,nausea,vomiting,and abdominal distension in patients with heartburn,reflux,and retrosternal pain symptoms.Results After treatment,22 patients in the observation group were cured,24 cases were effective,22 cases were effective and 7 cases were ineffective.The total effective rate reached 90.7%,which was higher than 76%of the control group(P<0.05).The results of endoscopy before treatment were similar between the two groups(P>0.05),and were improved after treatment.The number of grade 0 cases in the observation group was significantly increased,and the number of grade 3 cases was significantly decreased,and the improvement was better than that in the control group(P<0.05).Heartburn,reflux and retrosternal pain symptom scores in both groups were decreased after treatment(P<0.05),and the symptom scores in the observation group were lower than those in the control group after treatment(P<0.05).The ProGRP,PG-Ⅰand PG-Ⅱindexes in 2 groups were improved after treatment,and ProGRP indexes were increased,while ProgrpⅠand PG-Ⅱindexes were decreased(P<0.05).There were statistically significant differences in the indexes between 2 groups after treatment(P<0.05).In terms of adverse reactions,1 case of headache and 2 cases of abdominal distension occurred in the observation group,and the incidence of adverse reactions was 4%,lower than that of 13.3%in the control group(P<0.05).Conclusions Esomeprazole magnesium enteric-coated capsules are commonly used and effective drugs in the clinical treatment of patients with gastroesophageal reflux disease,but the effect of single drug is limited,and patients are prone to adverse reactions such as abdominal distension.Therefore,it is recommended to combine with other drugs such as Kangfuxin solution for treatment,which can improve the efficacy,improve symptoms and related indicators,and reduce the occurrence of adverse reactions.